Advancedadvanced biology
Cancer Genetics: Driver Mutations, Signatures, and Clonal Evolution
Learning objectives
- Distinguish oncogenes from tumor suppressor genes and explain their different genetic logic.
- Summarize the hallmarks of cancer as an organizing framework for diverse mutations.
- Interpret mutational signatures as records of the DNA-damage processes a tumor experienced.
- Explain clonal evolution and intratumor heterogeneity and their consequences for therapy.
- Evaluate how targeted therapies work and how resistance evolves.
Oncogenes and tumor suppressors: the genetic logic
Cancer genes fall into two classes with opposite genetics. Proto-oncogenes such as RAS, MYC, and EGFR normally promote growth; a single activating hit -- a point mutation locking Ras in its GTP-bound state, amplification of MYC, or the BCR-ABL translocation creating the Philadelphia chromosome -- converts one into a dominantly acting oncogene. Tumor suppressors such as RB1, TP53, BRCA1/2, and APC normally restrain growth, so both copies must be lost: Alfred Knudson's study of retinoblastoma showed that children inheriting one defective RB1 allele develop tumors when the second copy is somatically lost, the two-hit hypothesis. TP53 is the most commonly mutated gene in human cancer, found altered in roughly half of all tumors, because p53 integrates DNA damage, oncogene activation, and stress into arrest or apoptosis decisions. The catalog of cancer genes now exceeds 700, but most tumors are driven by a handful of key alterations layered onto a background of thousands of neutral passengers.
Hallmarks: organizing the complexity
Faced with bewildering genetic diversity, Douglas Hanahan and Robert Weinberg proposed in 2000 -- expanded in 2011 and 2022 -- that all cancers share a set of acquired capabilities, the hallmarks of cancer: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality (usually via telomerase), inducing angiogenesis, activating invasion and metastasis, deregulating cellular energetics, and avoiding immune destruction. Two enabling characteristics underlie them: genome instability, which generates the diversity selection acts on, and tumor-promoting inflammation. The framework's power is organizational rather than predictive -- it groups thousands of mutations into a finite set of phenotypic goals, guiding both research and drug design. Critics note it underplays tissue context: the same KRAS mutation drives pancreatic, lung, and colorectal cancers through partly different biology, and the tumor microenvironment -- fibroblasts, immune cells, vasculature -- is increasingly seen as a co-conspirator rather than a backdrop.
Mutational signatures: reading a tumor's history
Every mutagen leaves a fingerprint. By cataloging millions of somatic mutations across thousands of tumors, researchers extracted recurrent patterns -- COSMIC mutational signatures -- each reflecting a distinct DNA-damage or repair process. SBS1 arises from spontaneous deamination of methylated cytosine and ticks with age like a molecular clock; SBS4 marks tobacco smoke; SBS7 records ultraviolet damage; SBS2 and SBS13 betray the APOBEC enzymes, antiviral cytosine deaminases that sometimes turn on host DNA. Localized hypermutation storms called kataegis, often APOBEC-driven, can pepper small genomic regions. Signatures turn a tumor genome into an exposure diary: a lung tumor's SBS4 implicates smoking even without a patient history, and homologous-recombination-deficiency signatures predict response to PARP inhibitors. This archaeology is now entering clinics, where signature analysis helps classify cancers of unknown primary and match patients to therapies targeting the repair defect their mutations reveal.
Clonal evolution and heterogeneity
Peter Nowell proposed in 1976 that tumors evolve by clonal selection, and modern sequencing has confirmed it in spectacular detail. A tumor is not a uniform mass but a branching family tree: trunk mutations present in every cell mark early events, while branch mutations define subclones that diverged later, sometimes occupying distinct regions of the same tumor. Single-cell sequencing and circulating tumor DNA reveal this diversity without exhaustive biopsies. The clinical consequences are profound. A biopsy samples one branch and may miss the subclone carrying a resistance mutation; targeted therapy then prunes sensitive branches while inadvertently selecting resistant ones, the central dynamic of relapse. Metastases are often seeded by minor subclones, and their genomes can differ substantially from the primary tumor. Distinguishing driver mutations, which confer selective advantage, from passengers, which merely hitchhike, remains partly statistical -- recurrence across patients and functional assays are the arbiters -- and is essential for choosing drug targets.
A typical tumor carries thousands of mutations, but only a handful are drivers. Targeting a passenger mutation wastes therapy; misclassifying drivers risks missing the real vulnerabilities. Recurrence across patients and experimental validation separate the two.
Therapy, resistance, and open frontiers
Targeted therapy began with imatinib, which silences the BCR-ABL kinase of chronic myeloid leukemia and turned a fatal disease into a manageable one. EGFR inhibitors transformed subsets of lung cancer, BRAF plus MEK inhibition attacked melanoma, and PARP inhibitors exploit synthetic lethality in BRCA-deficient tumors. Immunotherapy added a second revolution: checkpoint inhibitors blocking PD-1 or CTLA-4 release T cells against tumors, producing durable remissions in melanoma, lung, and other cancers. Yet resistance is nearly universal. Tumors evolve gatekeeper mutations such as EGFR T790M that block drug binding, amplify the target, or reroute signaling through parallel pathways -- evolution in real time, predictable from first principles. The frontiers are early detection through liquid biopsy of circulating tumor DNA, intercepting minimal residual disease before relapse, and understanding why metastases, not primary tumors, kill -- the biology of dissemination and colonization remains the least understood chapter. Combination strategies that anticipate evolutionary escape routes, rather than reacting to them, define the current research agenda.
Key points
- Oncogenes act dominantly through activation; tumor suppressors require two hits, per Knudson's hypothesis.
- The hallmarks of cancer organize diverse mutations into shared acquired capabilities plus enabling instability.
- Mutational signatures (tobacco, UV, APOBEC, clock-like aging) record the damage processes a tumor experienced.
- Tumors are branching clonal populations; heterogeneity drives sampling bias and therapeutic resistance.
- Only a handful of a tumor's thousands of mutations are drivers; the rest are passengers.
- Targeted and immune therapies work, but evolution of gatekeeper mutations and bypass pathways drives relapse.
Common misconceptions
✓ Truth: Most cancers require multiple driver mutations accumulated over years -- typically 2 to 8 depending on tissue. A single oncogenic hit usually triggers senescence or apoptosis safeguards; malignancy needs those safeguards disabled too.
✓ Truth: The vast majority are passengers with no effect on fitness. Therapy must target drivers or the vulnerabilities they create. Sequencing reports therefore distinguish actionable drivers from background noise.
✓ Truth: Inheriting a BRCA1 or RB1 mutation raises risk substantially but does not guarantee cancer; the second hit and additional drivers are still required, and risk can be managed with surveillance or preventive measures.
Frequently asked questions
What is the difference between a driver and a passenger mutation?
A driver confers a selective growth advantage and is positively selected during tumor evolution; a passenger is neutral and merely hitchhikes along. Drivers recur across patients in the same gene and show functional effects in experiments, while passengers are essentially random background.
Why is TP53 mutated in so many cancers?
p53 sits at the crossroads of DNA damage, oncogene activation, and stress signaling, deciding between arrest, repair, senescence, and apoptosis. Disabling it removes multiple safeguards at once, giving emerging tumor cells an enormous selective advantage.
How do mutational signatures help patients?
They reveal the repair defects and exposures behind a tumor. A homologous-recombination-deficiency signature predicts benefit from PARP inhibitors; a high mutation burden from mismatch-repair loss predicts response to immunotherapy. Signatures thus guide therapy choice beyond single-gene tests.
Why do targeted therapies stop working?
Tumors evolve. Drug pressure selects subclones with gatekeeper mutations that block drug binding, target amplification, or bypass signaling through parallel pathways. This is why combinations and sequential strategies that anticipate escape routes are an active research focus.